An interventional study of Saline Enema (SE) and Glycerin Suppository in Meconium Obstruction of Prematurity, sponsored by KK Women's and Children's Hospital. Recruiting at 2 sites in Singapore. Open to participants aged 1 Day to 36 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by KK Women's and Children's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to study the effect of twice-daily saline enema (SE) in the treatment obstruction of prematurity (MOP) in infants with the birth weight ≤1.25kg. The main questions, the trial aims to answer are
The other aims of this study are to test whether the intervention is
Very low birth weight infants (VLBW ≤ 1.5 kg) constitute more than 60% of bed occupancy in level III neonatal units. They face the risk of 10-50% long-term disability, and their initial healthcare cost ranges from S$50,000 to 1 million, an important healthcare issue.
The incidence of meconium obstruction of prematurity (MOP) is 20-30% in extremely low birth weight (ELBW ≤ 1 kg) infants. The intervention based on the current standard of care increase the risk of laparotomy necrotizing enterocolitis, intestinal perforation, and neurodevelopmental risks posed by general anaesthesia. Our published pilot RCT demonstrated that saline enema (SE) is an effective, feasible, and safe intervention to reduce the time to reach full enteral feeds and is a potentially effective treatment for MOP in ELBW (\< 1 kg) infants.
Our primary hypothesis is that Infants with Twice-daily high-volume SE (20-40 ml/kg/day) intervention will result in reduced time to reach full enteral feeds compared to infants treated with conventional management with Glycerin suppository (GS) in (≤1.25kg) infants with MOP. Our exploratory hypothesis is that SE will have a protective effect on the gut microbiome, inflammatory and immune response in preterm infants.
Ninety-five infants born over three years in KK Hospital (KKH) and Singapore General Hospital (SGH) will be enrolled and randomized at 48 hours or later to receive SE or GS. The standardized protocol will be used for the accreditation and administration of SE. Primary, secondary, and exploratory outcomes data, including treatment failure data, will be recorded. Infants will be followed up to 36 weeks of gestation or discharge, whichever is earlier. Maternal and infant characteristics, inflammatory and immune response, and safety outcome data will be collected.
If the findings of our pilot trial are confirmed, the protocol can become the standard of care in preterm infants with MOP. Additionally, significant healthcare cost savings will be realized alongside an improved understanding of the Microbiome, immune and inflammatory response pertaining to the gut.
KK Women's and Children's Hospital is the lead sponsor of 137 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Criteria A: For infant presenting with early onset of MOP
Criteria B: For infant presenting with Late onset of MOP
Exclusion Criteria:
Infants that:
After randomisation, infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) earliest at 48 to 72 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier. SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds
Procedure: Saline Enema (SE)
Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned.
Drug: Glycerin Suppository
infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier. SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm
Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned.
Time to reach full enteral feeds in days
Time to reach full enteral feeds is measured from birth to the time infant reaches full oral milk feeds. Full oral milk feed is defined as milk volume of 110ml/kg/day. The total parenteral nutrition is discontinued when infant reaches milk feed volume of 110ml/kg/day. Rationale: SE loosens the thick and sticky meconium by saline absorption and triggers effective and strong peristaltic contractions, thereby leading to the evacuation of meconium from the gut. The evacuation of meconium leads to the resolution of the gut obstruction, thereby enhancing feed tolerance in premature infants with meconium obstruction of prematurity.
Time frame: Before 36 weeks of corrected age of discharge of the infant
Rate of treatment failure
Treatment failure is defined as the need to use additional treatment measures, apart from the study intervention to resolve MOP in the study cohort.
Time frame: Before 36 weeks of corrected age of discharge of the infant
Rate of (a) Culture positive sepsis (b) Necrotising enterocolitis.
Rationale: If twice daily SE leads to the shortening of time to reach full enteral feeds, resolution of MOP, and promote friendly bacteria microbiome, then it has the potential to reduce NICU stay, risk of necrotising enterocolitis, risk of sepsis, duration of total parenteral nutrition, duration of PICC and overall cost of care.
Time frame: Before 36 weeks of corrected age of discharge of the infant
Duration in days of (a) ICU stay (b) Total parenteral nutrition (c) PICC days.
Rationale: If twice daily SE leads to the shortening of time to reach full enteral feeds, resolution of MOP, and promote friendly bacteria microbiome, then it has the potential to reduce NICU stay, risk of necrotising enterocolitis, risk of sepsis, duration of total parenteral nutrition, duration of PICC and overall cost of care.
Time frame: Before 36 weeks of corrected age of discharge of the infant
Overall cost of care calculated in SGD at the time of discharge
Rationale: If twice daily SE leads to the shortening of time to reach full enteral feeds, resolution of MOP, and promote friendly bacteria microbiome, then it has the potential to reduce NICU stay, risk of necrotising enterocolitis, risk of sepsis, duration of total parenteral nutrition, duration of PICC and overall cost of care.
Time frame: Before 36 weeks of corrected age of discharge of the infant
Identification and quantification of bacteria from meconium/stool samples by DNA sequencing and analysis of top 50 bacteria Genus
Bacteria are identified from meconium/stools samples, collected at birth and weekly interval till discharge or 36 weeks of gestation
Time frame: Before 36 weeks of corrected age of discharge of the infant
To measure the serum level of IL 6 in pg/ml
Use Olink Target 48 platform to measure Rationale: To explore the relationship between gut microbiome and gut-brain axis
Time frame: Before 36 weeks of corrected age of discharge of the infant
To measure the serum level of neurotransmitters noradrenaline in pg/L
Use Norepinephrine ELISA Kit from abcam to measure
Time frame: Before 36 weeks of corrected age of discharge of the infant
Measure serum levels of dopamine in arbitrary units (peak area of analyte divided by peak area of an internal standard)
Use Norepinephrine ELISA Kit from abcam to measure
Time frame: Before 36 weeks of corrected age of discharge of the infant
Measure serum levels of serotonin in arbitrary units (peak area of analyte divided by peak area of an internal standard)
Use Norepinephrine ELISA Kit from abcam to measure
Time frame: Before 36 weeks of corrected age of discharge of the infant
Measure serum levels of GABA in arbitrary units (peak area of analyte divided by peak area of an internal standard)
Use Norepinephrine ELISA Kit from abcam to measure
Time frame: Before 36 weeks of corrected age of discharge of the infant
Measure level of Propionate in µM
Use Short Chain Fatty Acid Panel to measure
Time frame: Before 36 weeks of corrected age of discharge of the infant
Measure level of Butyrate in µM
Use Short Chain Fatty Acid Panel to measure
Time frame: Before 36 weeks of corrected age of discharge of the infant
Measure level of Acetate in µM
Use Short Chain Fatty Acid Panel to measure
Time frame: Before 36 weeks of corrected age of discharge of the infant
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for Aug 2027, 43 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meconium Ileus
KK Women's and Children's Hospital →